SCIENTIFIC PUBLICATIONS
The information contained in each post on this page was factually accurate on the date it was issued and posted.
2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster
A Novel Therapy for Refractory CBFA2T3::GLIS2-associated AMKL Using STRO-002 And Plerixafor
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 8, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), todayannounced that Bill Newell, Chief Executive...
2023 American Association for Cancer Research Annual Meeting (AACR) – Poster
Abstract #4849: The anti-ROR1 ADC STRO-003 demonstrates immune-modulating properties that may enhance checkpoint blockade Andrew McGeehan, Sihong Zhou, Dayson Moreira, Robert Yuan, Indrani Dutta, Jennifer Smith, Millicent Embry, Helena Kiefel, Xiaofan Li, Cuong Tran,...
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
ORLANDO, FL— April 18, 2023 — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded preclinical data for STRO-003, its ROR1...
13th Annual World ADC London 2023 – Presentation
Novel Precise Homosgenous ADCs Presented by: Kristin Bedard, SVP Drug Discovery
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 1, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers – Molecular Cancer Therapeutics – AACR Journals
41st Annual JP Morgan Healthcare Conference – Presentation
Update on STRO-002 Program and Plans for Registrational Trial in Advanced Ovarian Cancer – Presentation
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
- Results from the STRO-002 (luvelta) Phase 1 dose-expansion study demonstrate that FolRα-selected patients experienced meaningful clinical benefit, with 43.8% ORR, median DOR of 5.4 months, and median PFS of 6.6 months at the higher starting dose of 5.2mg/kg - -...